Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bleeding Disorders Clear all
Recruiting Phase 2 Interventional

A Randomized Multicenter Study for Isolated Skin Vasculitis

NCT02939573
View directory record Official record
Conditions
Primary Cutaneous Vasculitis, Cutaneous Polyarteritis Nodosa, IgA Vasculitis, Henoch-Schönlein Purpura
Interventions
Colchicine, Dapsone, Azathioprine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
12
States / cities
Kansas City, Kansas • Boston, Massachusetts • Rochester, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

NCT04755283
View directory record Official record
Conditions
Atrial Fibrillation (AF), Stroke
Interventions
Abelacimab, Rivaroxaban
Biological · Drug
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
55 Years and older
Enrollment
1,287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
28
States / cities
Huntsville, Alabama • Mobile, Alabama • Stamford, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Oral Health Intervention in Adult Primary Care

NCT06555029
View directory record Official record
Conditions
Dental Caries, Dry Mouth, Periodontal Diseases, Bleeding Gum
Interventions
EHR Changes, Medical Staff EHR Training, Clinician CSM theory-based didactic education and skills training, Standard ADA Oral Health Training
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
55 Years and older
Enrollment
929 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 10, 2026, 4:41 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Incidence of Bleeding on Probing as an Indicator of Peri-Implant Disease Progression

NCT06033859
View directory record Official record
Conditions
Peri-Implantitis, Bleeding of Subgingival Space
Interventions
Clinical measurements, Radiographic measurement, Dental prophylaxis or maintenance
Diagnostic Test · Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

NCT04370054
View directory record Official record
Conditions
Hemophilia A
Interventions
PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
19
States / cities
Mountain View, California • Oakland, California • Palo Alto, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Not applicable Interventional Results available

Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study

NCT01428713
View directory record Official record
Conditions
Menorrhagia
Interventions
Oral tranexamic acid, Oral Contraceptive Pills
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Sep 10, 2026, 4:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ultrasound Appearance of the Endometrium Post Radio-Frequency Ablation

NCT02584088
View directory record Official record
Conditions
Menorrhagia
Interventions
Ultrasound
Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 3 Interventional

Decompression Intervention of Variceal Rebleeding Trial (DIVERT)

NCT00006161
View directory record Official record
Conditions
Esophageal and Gastric Varices, Liver Cirrhosis
Interventions
Transjugular Intrahepatic Portosystemic Shunt (TIPS), Distal Splenorenal Shunt
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
5
States / cities
Miami, Florida • Atlanta, Georgia • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

NCT07285460
View directory record Official record
Conditions
Hemophilia
Interventions
Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
1 Year to 11 Years · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage

NCT05245227
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Sublingual Misoprostol, IV Oxytocin
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 10, 2026, 4:41 PM EDT
Active, not recruiting No phase listed Observational

Illuminating Neuropsychological Dysfunction and Systemic Inflammatory Mechanisms Gleaned After Hospitalization in Trauma-ICU Study

NCT03098459
View directory record Official record
Conditions
Delirium, Cognitive Impairment, Alzheimer; Early Onset, Trauma, Polytrauma, Traumatic Brain Injury, ICU, Critical Illness
Interventions
Non-interventional observational prospective cohort study
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

NCT01561391
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
activated recombinant human factor VII, factor IX, factor VIII
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
5 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
14
States / cities
Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Sep 10, 2026, 4:41 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

NCT03275740
View directory record Official record
Conditions
Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant, Placebo subcutaneous healthy participant, PF-06755347 subcutaneous ITP
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting No phase listed Observational

Investigation of the Genetics of Hematologic Diseases

NCT02720679
View directory record Official record
Conditions
Bone Marrow Failure Syndromes, Erythrocyte Disorder, Leukocyte Disorder, Hemostasis, Blood Coagulation Disorder, Sickle Cell Disease, Dyskeratosis Congenita, Diamond-Blackfan Anemia, Congenital Thrombocytopenia, Severe Congenital Neutropenia, Fanconi Anemia, Myelodysplastic Syndromes, Myeloproliferative Diseases
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
1,716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2050
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Not applicable Interventional

Assessing Pain and Effectiveness of Carevix Device for IUD Insertions

NCT07290517
View directory record Official record
Conditions
IUD, Abnormal Uterine Bleeding, Pain, Cervical
Interventions
Carevix, Tenaculum
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

EXTEND (Eltrombopag Extended Dosing Study)

NCT00351468
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag olamine (SB-497115-GR)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
23
States / cities
Huntsville, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Not applicable Interventional

Auricular VNS Following Intracerebral Hemorrhage

NCT06799390
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Auricular Vagus Nerve Stimulation, Sham Auricular Vagus nerve Stimulation
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 4 Interventional

Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery

NCT00092976
View directory record Official record
Conditions
Hemophilia A
Interventions
ReFacto
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
6 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
4
States / cities
Los Angeles, California • New Brunswick, New Jersey • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Not applicable Interventional

Auricular VNS Following Subarachnoid Hemorrhage

NCT04557618
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Auricular Vagus Nerve Stimulation, Sham Auricular Vagus nerve Stimulation
Device
Lead sponsor
Anna Huguenard
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Not applicable Interventional Results available

Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH

NCT01137110
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Brief LEV, Extended LEV
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 99 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome

NCT00475020
View directory record Official record
Conditions
Myelofibrosis
Interventions
Busulfan, Fludarabine, Thymoglobulin (ATG)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Sep 10, 2026, 4:41 PM EDT
Terminated Phase 2 Interventional Results available

Antithrombin III in Infectious Disease Caused by COVID-19

NCT04899232
View directory record Official record
Conditions
Antithrombin III Deficiency, Covid19
Interventions
Antithrombin III
Drug
Lead sponsor
Enrique Ginzburg
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pacifier Activated Device and Mother's Voice in Infants at High-risk for Cerebral Palsy

NCT03230032
View directory record Official record
Conditions
Infant Development, Infant,Premature, Hydrocephalus, Neonatal Encephalopathy, Infarction, PVL, Thrombosis, Intraventricular Hemorrhage
Interventions
pacifier-activated device
Device
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
32 Weeks to 12 Months
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 10, 2026, 4:41 PM EDT